Law360, Los Angeles (July 26, 2017, 9:27 PM EDT) -- Antitrust regulators this year have dished out far fewer cartel fines than a year earlier as investigations into the automotive and financial industries wind down, but pharmaceutical companies may soon be subject to closer regulatory looks, according to a report Tuesday by Morgan Lewis & Bockius LLP.